Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20–243 CrossMab

Although rituximab has revolutionized the treatment of hematological malignancies, the acquired resistance is one of the prime obstacles for cancer treatment, and development of novel CD20-targeting antibodies with potent anti-tumor activities and specificities is urgently needed. Emerging evidence...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Zhao, Lei, Xie, Feiyue, Tong, Xin, Li, Huafei, Chen, Yaling, Qian, Weizhu, Duan, Shuyan, Zheng, Juan, Zhao, Ziye, Li, Bohua, Zhang, Dapeng, Zhao, Jian, Dai, Jianxin, Hou, Sheng, Guo, Yajun
Formato: Artigo
Idioma:Inglês
Publicado: Landes Bioscience 2014
Assuntos:
Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4011918/
https://ncbi.nlm.nih.gov/pubmed/24670986
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.28613
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares